Zymeworks to Announce Q3 2025 Financial Results and Host Conference Call

An announcement from Zymeworks ( (ZYME) ) is now available.

Zymeworks Inc. announced it will report its third quarter 2025 financial results on November 6, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update. This announcement highlights the company’s ongoing efforts to advance its pipeline of therapeutic candidates and maintain transparency with stakeholders, potentially impacting its market position and investor confidence.

The most recent analyst rating on (ZYME) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.

Spark’s Take on ZYME Stock

According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.

Zymeworks’ overall score is driven by strong earnings call insights, including revenue growth and regulatory successes. However, financial performance and valuation concerns, particularly profitability and cash flow issues, weigh down the score. Technical analysis provides a positive outlook, but the negative P/E ratio and lack of dividends are significant detractors.

To see Spark’s full report on ZYME stock, click here.

More about Zymeworks

Zymeworks Inc. is a global clinical-stage biotechnology company focused on discovering, developing, and commercializing novel, multifunctional biotherapeutics. The company aims to improve the standard of care for difficult-to-treat conditions such as cancer, inflammation, and autoimmune diseases. Zymeworks is known for its proprietary Azymetric™ technology and has developed zanidatamab, a HER2-targeted bispecific antibody, which has received various approvals for treating HER2-positive biliary tract cancer.

Average Trading Volume: 538,818

Technical Sentiment Signal: Buy

Current Market Cap: $1.41B

Learn more about ZYME stock on TipRanks’ Stock Analysis page.